ClinicalTrialsFinder

DZD6008 Clinical Trials

4 recruitingDrug
Phase 14Phase 22

Showing 1–4 of 4 trials

Recruiting
Phase 1

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

Dizal Pharmaceuticals140 enrolled5 locationsNCT06905197
Recruiting
Phase 1

Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)

Dizal Pharmaceuticals190 enrolled1 locationNCT06813365
Recruiting
Phase 1Phase 2

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

Dizal (Jiangsu) Pharmaceutical Co., Ltd.200 enrolled4 locationsNCT07079475
Recruiting
Phase 1Phase 2

DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

Dizal Pharmaceuticals100 enrolled1 locationNCT07070440